BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 33339442)

  • 1. Epigenetic Modifier SETD8 as a Therapeutic Target for High-Grade Serous Ovarian Cancer.
    Wada M; Kukita A; Sone K; Hamamoto R; Kaneko S; Komatsu M; Takahashi Y; Inoue F; Kojima M; Honjoh H; Taguchi A; Kashiyama T; Miyamoto Y; Tanikawa M; Tsuruga T; Mori-Uchino M; Wada-Hiraike O; Osuga Y; Fujii T
    Biomolecules; 2020 Dec; 10(12):. PubMed ID: 33339442
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Histone methyltransferases EHMT1 and EHMT2 (GLP/G9A) maintain PARP inhibitor resistance in high-grade serous ovarian carcinoma.
    Watson ZL; Yamamoto TM; McMellen A; Kim H; Hughes CJ; Wheeler LJ; Post MD; Behbakht K; Bitler BG
    Clin Epigenetics; 2019 Nov; 11(1):165. PubMed ID: 31775874
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epigenetic siRNA and Chemical Screens Identify SETD8 Inhibition as a Therapeutic Strategy for p53 Activation in High-Risk Neuroblastoma.
    Veschi V; Liu Z; Voss TC; Ozbun L; Gryder B; Yan C; Hu Y; Ma A; Jin J; Mazur SJ; Lam N; Souza BK; Giannini G; Hager GL; Arrowsmith CH; Khan J; Appella E; Thiele CJ
    Cancer Cell; 2017 Jan; 31(1):50-63. PubMed ID: 28073004
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of a selective, substrate-competitive inhibitor of the lysine methyltransferase SETD8.
    Ma A; Yu W; Li F; Bleich RM; Herold JM; Butler KV; Norris JL; Korboukh V; Tripathy A; Janzen WP; Arrowsmith CH; Frye SV; Vedadi M; Brown PJ; Jin J
    J Med Chem; 2014 Aug; 57(15):6822-33. PubMed ID: 25032507
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Histone methyltransferase SMYD2 selective inhibitor LLY-507 in combination with poly ADP ribose polymerase inhibitor has therapeutic potential against high-grade serous ovarian carcinomas.
    Kukita A; Sone K; Oda K; Hamamoto R; Kaneko S; Komatsu M; Wada M; Honjoh H; Kawata Y; Kojima M; Oki S; Sato M; Asada K; Taguchi A; Miyasaka A; Tanikawa M; Nagasaka K; Matsumoto Y; Wada-Hiraike O; Osuga Y; Fujii T
    Biochem Biophys Res Commun; 2019 May; 513(2):340-346. PubMed ID: 30955858
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SETD8 stabilized by USP17 epigenetically activates SREBP1 pathway to drive lipogenesis and oncogenesis of ccRCC.
    Li X; Liu Z; Xia C; Yan K; Fang Z; Fan Y
    Cancer Lett; 2022 Feb; 527():150-163. PubMed ID: 34942305
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Histone Methyltransferase SETD8 Regulates the Expression of Tumor Suppressor Genes via H4K20 Methylation and the p53 Signaling Pathway in Endometrial Cancer Cells.
    Kukita A; Sone K; Kaneko S; Kawakami E; Oki S; Kojima M; Wada M; Toyohara Y; Takahashi Y; Inoue F; Tanimoto S; Taguchi A; Fukuda T; Miyamoto Y; Tanikawa M; Mori-Uchino M; Tsuruga T; Iriyama T; Matsumoto Y; Nagasaka K; Wada-Hiraike O; Oda K; Hamamoto R; Osuga Y
    Cancers (Basel); 2022 Oct; 14(21):. PubMed ID: 36358786
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The histone methyltransferase WHSC1 is regulated by EZH2 and is important for ovarian clear cell carcinoma cell proliferation.
    Kojima M; Sone K; Oda K; Hamamoto R; Kaneko S; Oki S; Kukita A; Machino H; Honjoh H; Kawata Y; Kashiyama T; Asada K; Tanikawa M; Mori-Uchino M; Tsuruga T; Nagasaka K; Matsumoto Y; Wada-Hiraike O; Osuga Y; Fujii T
    BMC Cancer; 2019 May; 19(1):455. PubMed ID: 31092221
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SETD8 potentiates constitutive ERK1/2 activation via epigenetically silencing DUSP10 expression in pancreatic cancer.
    Liu M; Qin Y; Hu Q; Liu W; Ji S; Xu W; Fan G; Ye Z; Zhang Z; Xu X; Yu X; Zhuo Q
    Cancer Lett; 2021 Feb; 499():265-278. PubMed ID: 33232789
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Histone lysine methyltransferase SETD8 promotes carcinogenesis by deregulating PCNA expression.
    Takawa M; Cho HS; Hayami S; Toyokawa G; Kogure M; Yamane Y; Iwai Y; Maejima K; Ueda K; Masuda A; Dohmae N; Field HI; Tsunoda T; Kobayashi T; Akasu T; Sugiyama M; Ohnuma S; Atomi Y; Ponder BA; Nakamura Y; Hamamoto R
    Cancer Res; 2012 Jul; 72(13):3217-27. PubMed ID: 22556262
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epigenetic Determinants of Erythropoiesis: Role of the Histone Methyltransferase SetD8 in Promoting Erythroid Cell Maturation and Survival.
    DeVilbiss AW; Sanalkumar R; Hall BD; Katsumura KR; de Andrade IF; Bresnick EH
    Mol Cell Biol; 2015 Jun; 35(12):2073-87. PubMed ID: 25855754
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SETD8 promotes stemness characteristics and is a potential prognostic biomarker of gastric adenocarcinoma.
    Piao L; Che N; Li H; Li M; Feng Y; Liu X; Kim S; Jin Y; Xuan Y
    Exp Mol Pathol; 2020 Dec; 117():104560. PubMed ID: 33127342
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The PPARγ-SETD8 axis constitutes an epigenetic, p53-independent checkpoint on p21-mediated cellular senescence.
    Shih CT; Chang YF; Chen YT; Ma CP; Chen HW; Yang CC; Lu JC; Tsai YS; Chen HC; Tan BC
    Aging Cell; 2017 Aug; 16(4):797-813. PubMed ID: 28514051
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ROR2 induces cell apoptosis via activating IRE1α/JNK/CHOP pathway in high-grade serous ovarian carcinoma in vitro and in vivo.
    Li R; Liu T; Shi J; Luan W; Wei X; Yu J; Mao H; Liu P
    J Transl Med; 2019 Dec; 17(1):428. PubMed ID: 31878941
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structure-activity relationship studies of SETD8 inhibitors.
    Ma A; Yu W; Xiong Y; Butler KV; Brown PJ; Jin J
    Medchemcomm; 2014 Dec; 5(12):1892-1898. PubMed ID: 25554733
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SETD8 involved in the progression of inflammatory bowel disease via epigenetically regulating p62 expression.
    Chen P; Zhu H; Mao Y; Zhuo M; Yu Y; Chen M; Zhao Q; Li L; Wu M; Ye M
    J Gastroenterol Hepatol; 2021 Oct; 36(10):2850-2863. PubMed ID: 33991018
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The peroxisome proliferator-activated receptor gamma/retinoid X receptor alpha heterodimer targets the histone modification enzyme PR-Set7/Setd8 gene and regulates adipogenesis through a positive feedback loop.
    Wakabayashi K; Okamura M; Tsutsumi S; Nishikawa NS; Tanaka T; Sakakibara I; Kitakami J; Ihara S; Hashimoto Y; Hamakubo T; Kodama T; Aburatani H; Sakai J
    Mol Cell Biol; 2009 Jul; 29(13):3544-55. PubMed ID: 19414603
    [TBL] [Abstract][Full Text] [Related]  

  • 18. USP29 Deubiquitinates SETD8 and Regulates DNA Damage-Induced H4K20 Monomethylation and 53BP1 Focus Formation.
    Hernández-Reyes Y; Paz-Cabrera MC; Freire R; Smits VAJ
    Cells; 2022 Aug; 11(16):. PubMed ID: 36010569
    [TBL] [Abstract][Full Text] [Related]  

  • 19. GATA3 as a master regulator for interactions of tumor-associated macrophages with high-grade serous ovarian carcinoma.
    El-Arabey AA; Denizli M; Kanlikilicer P; Bayraktar R; Ivan C; Rashed M; Kabil N; Ozpolat B; Calin GA; Salama SA; Abd-Allah AR; Sood AK; Lopez-Berestein G
    Cell Signal; 2020 Apr; 68():109539. PubMed ID: 31935430
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genome-wide methylation profiling of ovarian cancer patient-derived xenografts treated with the demethylating agent decitabine identifies novel epigenetically regulated genes and pathways.
    Tomar T; de Jong S; Alkema NG; Hoekman RL; Meersma GJ; Klip HG; van der Zee AG; Wisman GB
    Genome Med; 2016 Oct; 8(1):107. PubMed ID: 27765068
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.